XML 57 R48.htm IDEA: XBRL DOCUMENT v3.22.2
Balance Sheet Components - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Jul. 31, 2021
Schedule of Available-for-sale Securities [Line Items]            
Cash and cash equivalents $ 167,758,000   $ 167,758,000   $ 171,223,000  
Other-than-temporary impairment loss 0 $ 0 0 $ 0    
API and bulk drug product price true-up 54,443,000   54,443,000    
Acquired In Process Research And Development Asset     35,000,000  
Profit share liability 6,897,000   $ 6,897,000   15,857,000  
Eluminex [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Unbilled upfront payment           $ 8,000,000.0
Maximum [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Contractual maturities of available-for-sale investments     2 years      
Foreign subsidiaries [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Cash and cash equivalents $ 98,800,000   $ 98,800,000   $ 91,200,000